18:03:26 Europe / Stockholm

Kurs & Likviditet

Kursutveckling och likviditet under dagen för detta pressmeddelande

Prenumeration

Kalender

2024-04-03 Årsstämma 2024
2024-02-28 Bokslutskommuniké 2023
2023-11-01 Extra Bolagsstämma 2023
2023-08-25 Kvartalsrapport 2023-Q2

Beskrivning

LandDanmark
ListaMid Cap Copenhagen
SektorHälsovård
IndustriMedicinteknik
Gubra är ett läkemedelsbolag. Bolagets verksamhet är fokuserad på de tidiga stadierna av läkemedelsutveckling. De driver huvudsakligen forskning och utveckling inom området för metabola och fibrotiska sjukdomar.. Bolagets produktportfölj innefattar ett flertal varumärken och läkemedel, och verksamheten bedrivs på global nivå, med störst närvaro inom Nordamerika och Norden. Huvudkontoret ligger i Hørsholm, Danmark.
2023-05-17 07:30:00
  • BI 1820237 a novel long-acting neuropeptide Y receptor type 2 (NPY2) agonist, has been evaluated in a phase 1 clinical trial.
  • Results to be presented today at the ECO 2023 congress in Dublin, Ireland.
  • The trial showed no unexpected safety concerns, and positive effects on energy intake and gastric emptying.
  • BI 1820237 originates from an ongoing collaboration between Boehringer Ingelheim and Gubra A/S.

 
Today, at the 30th European Congress on Obesity (ECO 2023) in Dublin, Ireland, Boehringer Ingelheim shares phase 1 results for BI 1820237, a long acting NPY2 receptor agonist drug candidate developed in collaboration with Gubra A/S.

The phase 1 trial (NCT04903509) was a placebo-controlled study consisting of 3 parts: Part 1: testing single increasing subcutaneous doses of the novel NPY2 receptor agonist, part 2: increasing the number of participants in the high dose group and part 3:  exploring low-to-medium doses of the NPY2 receptor agonist in combination with low-dose liraglutide. Participants in the trial were healthy men with overweight/obesity. The results show no unexpected safety or tolerability concerns with single doses of BI 1820237 with and without liraglutide. Adverse events were primarily gastro-intestinal in nature and the frequency increased with increasing dose. Treatment with BI 1820237 decreased energy intake and delayed gastric emptying in healthy men with overweight/obesity, supporting further investigations of the drug candidate.
 
Niels Vrang, Chief Scientific Officer at Gubra A/S, expressed satisfaction with the results and the continued development of this peptide by Boehringer Ingelheim as a potential anti-obesity medication:
 
“We are excited to see data from the phase 1 trial presented by Boehringer Ingelheim at the annual European Congress on Obesity. Data are in line with observations in several animal models. We look forward to seeing how this NPY2-receptor agonist can be used in combination with approved obesity drugs, e.g. GLP-1 receptor agonists and other obesity drug candidates currently in development, to potentially improve therapy - better effect and/or a better tolerability profile for the benefit for people living with obesity. It will be exciting to follow this project as it moves forward.”